Neuropsychiatry-Focused Alto Neuroscience's Mid-Stage Depression Trial Disappoints, Analyst Notes Failure Raises Concerns About Platform

On Tuesday, Alto Neuroscience, Inc. ANRO revealed that the Phase 2b study of ALTO-100 for major depressive disorder (MDD) did not meet its primary endpoint compared to placebo.The biomarker-defined major depressive disorder patient group treated with ALTO-100 did not demonstrate a statistically significant improvement in depressive symptoms compared to placebo.ALTO-100 did not demonstrate a benefit over the placebo on the pre-specified key secondary analyses.Also Read: Treatment Patch For Schizophrenia: New ...